Antineoplastic Agents, Hormonal

"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Descriptor ID	D018931
MeSH Number(s)	D27.505.954.248.169
Concept/Terms	Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Hormonal Agents, Antineoplastic Hormonal Antineoplastic Agents Hormonal Antineoplastics Antineoplastic Hormonal Drugs Drugs, Antineoplastic Hormonal Hormonal Drugs, Antineoplastic Hormonal Antineoplastic Drugs Antineoplastics, Hormonal Antineoplastic Hormonal Agents Agents, Antineoplastic Hormonal Antineoplastic Drugs, Hormonal

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Hormonal [D27.505.954.248.169]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Hormonal".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.

Bar chart showing 25 publications over 16 distinct years, with a maximum of 3 publications in 2005 and 2015 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	2	1	3
2008	1	0	1
2009	0	1	1
2010	2	0	2
2011	1	1	2
2012	1	0	1
2013	1	0	1
2014	1	0	1
2015	1	2	3
2016	1	0	1
2017	1	2	3
2018	1	0	1
2019	1	1	2
2020	1	0	1
2021	1	0	1
2024	1	0	1

Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.

Chang CY, Jones BL, Hincapie-Castillo JM, Park H, Heldermon CD, Diaby V, Wilson DL, Lo-Ciganic WH. Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors. Br J Cancer. 2024 Jun; 130(12):1943-1950.

View in: PubMed
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.

View in: PubMed
Mavingire N, Campbell P, Wooten J, Aja J, Davis MB, Loaiza-Perez A, Brantley E. Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes. Cancer Lett. 2021 03 01; 500:64-74.

View in: PubMed
Shah CH, Balkrishnan R, Diaby V, Xiao H. Examining factors associated with adherence to hormonal therapy in breast cancer patients. Res Social Adm Pharm. 2020 04; 16(4):574-582.

View in: PubMed
M?rquez-Garb?n DC, Deng G, Comin-Anduix B, Garcia AJ, Xing Y, Chen HW, Cheung-Lau G, Hamilton N, Jung ME, Pietras RJ. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. J Steroid Biochem Mol Biol. 2019 10; 193:105415.

View in: PubMed
Ali AA, Tawk R, Xiao H, Campbell E, Semykina A, Montero AJ, Mogos M, Diaby V. Comparative effectiveness of radiotherapy for early-stage hormone receptor-positive breast cancer in elderly women using real-world data. Cancer Med. 2019 01; 8(1):117-127.

View in: PubMed
Ustjanauskas AE, Quinn GP, Pan TM, Rivera M, V?zquez-Otero C, Ung D, Roetzheim RG, Laronga C, Johnson K, Norton M, Carrizosa C, Mu?oz D, Goldenstein M, Nuhaily S, Wells KJ. Facilitators of Survivorship Care Among Underserved Breast Cancer Survivors: a Qualitative Study. J Cancer Educ. 2017 Dec; 32(4):756-763.

View in: PubMed
Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget. 2017 Jul 18; 8(29):47916-47930.

View in: PubMed
Vetterlein MW, L?ppenberg B, Karabon P, Dalela D, Jindal T, Sood A, Chun FK, Trinh QD, Menon M, Abdollah F. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer. Cancer. 2017 Sep 01; 123(17):3241-3252.

View in: PubMed
Wells KJ, Pan TM, V?zquez-Otero C, Ung D, Ustjanauskas AE, Mu?oz D, Laronga C, Roetzheim RG, Goldenstein M, Carrizosa C, Nuhaily S, Johnson K, Norton M, Sims E, Quinn GP. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer. 2016 10; 24(10):4123-30.

View in: PubMed

People

Explore

Similar Concepts

Top Journals